IFNGR1 and glioblastoma: To determine the universality of the IFNγR pathway as a new resistance mechanism in addition to glioblastoma, authors tested other solid tumors such as pancreatic tumor cells (AsPC-1 and BxPC-3), ovarian cancer cells (SKOV3), and lung cancer cells (A549).